Allogeneic hematopoietic cell transplantation (allo-HCT) is feasible in older patients with myelodysplastic syndrome (MDS), ...

NMDPSM, a global nonprofit leader in cell therapy, and its collaborative research program, CIBMTR (Center for International Blood and Marrow Transplant Research), have released revised donor and cord ...

Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis ...

Although allogeneic hematopoietic cell transplantation (HCT) offers a potential for cure for many patients with advanced hematologic malignancies and bone marrow failure or immunodeficiency syndromes, ...

Post-transplantation cyclophosphamide (PTCy) led to similar overall survival (OS) and graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) in patients who received a hematopoietic stem ...

The researchers assessed outcomes 3 years following allo-HCT transplant and compared outcomes between patients treated from 2000 to 2009 (n = 728), 2010 to 2014 (n = 1,775), and 2015 to 2021 (n ...

While high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT) can deepen remissions and improve outcomes for multiple myeloma, these treatments come with significant risks ...

All 97 patients in the study had pulmonary function testing performed before HCT, and 91, 72, and 55 patients had follow-up testing data available at years 1, 2, and 3, respectively, after HCT.

“Transplantation is global and CareDx is proud to expand its leadership in Europe with CE marked AlloSeq HCT to help improve care for hematopoietic cell transplant patients,” said Reg Seeto ...

Key takeaways: When comparing median FEV 1 before vs. 3 years after hematopoietic cell transplant, researchers found similar levels.; Diffusing capacity of the lungs for carbon monoxide was ...